New combo treatment shows promise for inoperable liver cancer
NCT ID NCT05532319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new treatment for people with liver cancer that cannot be removed by surgery. The treatment combines chemotherapy delivered directly to the liver, a procedure to block the tumor's blood supply, and two drugs (lenvatinib and tislelizumab). The goal was to see if this combination could help control the cancer and improve survival. The study involved 64 participants and has been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China